Preclinical safety of anecortave acetate.
A number of preclinical safety pharmacology and toxicity studies have been performed on the angiostatic cortisene anecortave acetate in various species and using different routes of administration (oral, intravenous, subcutaneous, topical ocular, intraocular injection, posterior juxtascleral) and a wide range of doses (0-1,000 mg/kg). Anecortave acetate did not interact with a broad panel of pharmacological receptors and had no apparent pharmacological effects on major organ systems including the central nervous, gastrointestinal, renal, cardiovascular, and respiratory systems. Oral, topical ocular, and posterior juxtascleral administration of anecortave acetate had no significant ocular or systemic side effects or toxicity. In addition, there was no significant carcinogenic or reproductive/developmental toxicity associated with anecortave acetate in genotoxicity, carcinogenicity, and reproductive toxicity studies.
Heaton
Jim
J
Toxicology and In Vivo Pharmacology, Alcon Research, Ltd., Fort Worth, Texas 76134, USA.
Kastner
Philip
P
Hackett
Robert
R
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000633:toxicity*; D000818:Animals; D015197:Carcinogenicity Tests; D004353:Drug Evaluation, Preclinical; D005123:Eye / Q000098:blood supply; D009152:Mutagenicity Tests; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011244:Pregnadienediols / Q000494:pharmacology / Q000633:toxicity*
D020533:Angiogenesis Inhibitors; D011244:Pregnadienediols; C418047:anecortave acetate